Bob Rambo

Bio:

Bob Rambo joined NewAmsterdam Pharma as Executive Vice President of Marketing in January 2023 and had supported NewAmsterdam’s initial commercial and medical affairs efforts as a consultant since November 2021. Prior to his current role, Bob had a successful 32‑year career at Merck, where he held multiple leadership roles across marketing, medical, and sales—launched brands that routinely exceeded multi‑billion dollar targets. His marketing leadership helped propel Merck’s Hepatitis C franchise to $1.7 billion in annual sales within two years, marking it as the second‑most successful launch at Merck. In a variety of medical affairs and marketing leadership roles, he also helped drive the U.S. ezetimibe franchise (Zetia and Vytorin) to over $4 billion in peak annual sales. Bob has been consistently recognized for surpassing sales objectives while empowering diverse, high-performing teams. He is a therapeutic expert in lipids and cardiology, having spent a significant portion of his career focused on cholesterol treatments—including statins, ezetimibe products, and cholesteryl ester transfer protein inhibitors.

Bob holds an MBA from the Fox School of Business and a BS in Microbiology from Penn State University.